Cross-over comparison of tamoxifen and aminoglutethimide in advanced breast cancer

Harold Harvey, Allan Lipton, D. S. White, R. J. Santen, A. E. Boucher, A. S. Shafik, R. J. Dixon

Research output: Contribution to journalArticle

33 Scopus citations

Abstract

Thirty-four postmenopausal patients with advanced breast cancer had an overall objective response rate of 47% when treated with aminoglutethimide and hydrocortisone initially and a response rate of 24% when crossed over to therapy with tamoxifen after progression on aminoglutethimide. A similar group of 32 patients experienced a response rate of 28% when treated with tamoxifen first and a 19% objective response rate on subsequent therapy with aminoglutethimide. Patients who failed to respond to the first therapy seldom responded on cross-over to the alternate therapy. Toxicities were acceptable with both forms of therapy. Tamoxifen and aminoglutethimide used sequentially are effective forms of palliative hormonal therapy in metastatic breast cancer.

Original languageEnglish (US)
Pages (from-to)3451s-3453s
JournalCancer Research
Volume42
Issue number8 Suppl.
StatePublished - Dec 1 1982

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Cross-over comparison of tamoxifen and aminoglutethimide in advanced breast cancer'. Together they form a unique fingerprint.

  • Cite this

    Harvey, H., Lipton, A., White, D. S., Santen, R. J., Boucher, A. E., Shafik, A. S., & Dixon, R. J. (1982). Cross-over comparison of tamoxifen and aminoglutethimide in advanced breast cancer. Cancer Research, 42(8 Suppl.), 3451s-3453s.